MXCT
MaxCyte, Inc.1.4700
-0.0200-1.34%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Headwinds transitory; DTX gains traction
Q&A largely reaffirmed prepared remarks on $4 million core revenue headwinds from SPL customer program losses and largest partner's inventory drawdown, but management stressed these are transitory and customer-specific—not demand deterioration—with industry recovery as upside to $25-27 million core guide. Early ExPERT DTX sales hit Q1 from beta users and new customers, including Asia-Pacific, signaling H2 ramp. Expect 3+ new SPLs by early H2 and 2-4 pivotal milestones this year. Cell therapy demand rebounds on complex edits favoring their platform. Q1 core tracks ~$6 million. Management stays bullish.
Key Stats
Market Cap
156.81MP/E (TTM)
-Basic EPS (TTM)
-0.43Dividend Yield
0%Recent Filings
8-K
MaxCyte names new CFO
MaxCyte appointed Parmeet Ahuja as CFO effective March 30, 2026, succeeding Douglas Swirsky. Ahuja, with over 20 years at Agilent in finance and IR, gets $450,000 base, 50% target bonus, options for 375,000 shares, and RSUs for 187,500 shares. His expertise bolsters financial operations amid growth. No family ties or special arrangements disclosed.
10-K
FY2025 results
MaxCyte posted FY2025 revenue of $33M, down 15% y/y from $38.6M amid fewer SPL milestones ($3.4M vs $6.1M) and softer PA sales ($11.9M, -15%). Core revenue fell 9% to $29.6M, with instruments flat at $6.8M and licenses off 13% to $8.9M; gross margins held at 81%. Q4 momentum lacked disclosure, but restructuring cut headcount 34%, trimming opEx to $78.7M (R&D $20.8M, sales/marketing $18.9M). Cash burn eased to $34M from ops; $103M runway supports pivot. Customer milestones stalled. SeQure buy added assays, but goodwill fully impaired ($3.6M). Nasdaq delisting risk looms on sub-$1 bid.
8-K
MaxCyte Q4 revenue $7.3M
MaxCyte reported Q4 2025 revenue of $7.3 million, down 16% year-over-year, and full-year revenue of $33.0 million, off 15%, hit by a 15% drop from its largest SPL customer. Cash stands at $155.6 million; guides 2026 revenue to $30-32 million with core at $25-27 million. Signed 4 new SPLs, boosting total to 32. Cash burn slashed over $16 million.
8-K
Nasdaq bid price deficiency
8-K
Preliminary 2025 results released
MaxCyte released preliminary unaudited Q4 and full-year 2025 results on January 12, 2026, with core revenue hitting $6.6-6.7M for the quarter and $29.5-29.6M annually, alongside $3.3-3.5M in SPL revenue for the year. Cash stands at ~$155.6M. Cash is substantial. Management touts cost cuts and expects revenue growth in H2 2026 amid macro headwinds.
BLFS
BioLife Solutions, Inc.
24.61-0.04
CTKB
Cytek Biosciences, Inc.
4.70+0.06
CTSO
Cytosorbents Corporation
0.64+0.01
IART
Integra LifeSciences Holdings C
13.00-0.47
LAB
Standard BioTools Inc.
1.49-0.02
MASS
908 Devices Inc.
5.78-0.13
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
97.72-0.85
PLSE
Pulse Biosciences, Inc
14.23+0.10
RCEL
Avita Medical, Inc.
3.33-0.07